| abstract |
The present invention relates to compounds of the formula wherein R 1 and R 2 represent, independently of one another, hydrogen, lower alkyl, lower alkoxy or halogen; R3 is phenyl, optionally substituted with lower alkyl, CF3, lower alkoxy or halogen; and R4 is hydrogen, lower alkyl, lower alkenyl, -C- (O) -lower alkyl, -C (O) -phenyl, lower alkyl-C (O) -phenyl, lower alkylene-C- (O) O-lower alkyl, lower alkantri-yl-di-C- (O) O-lower alkyl, hydroxy-lower alkyl, lower alkyl-O-lower alkyl, lower alkyl-CH (OH) CF3, phenyl or benzyl, R5 and R6 are, independently of one another, hydrogen, phenyl, lower alkyl or di-lower alkyl or together may form a phenyl ring, and R5 and one of R1 or R2 may together form a saturated or unsaturated 6-membered ring, A is 4-7- members a saturated ring which may contain a heteroatom such as O or S, and to their pharmaceutically acceptable acid addition salts, which are OFQ receptor agonists and / or antagonists. |